MRSN · As filed with the SEC
Mersana Therapeutics income statement, by fiscal year
The statement as Mersana Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 | FY2017 Year ended Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | 40,497 | 36,855 | 26,581 | 43 | 828 | 42,123 | 10,594 | — |
| Operating expenses: | ||||||||
| Research and development expense: | 73,020 | 148,269 | 173,385 | 132,013 | 67,036 | 55,040 | 59,915 | 46,700 |
| General and administrative expense | 40,813 | 59,543 | 56,963 | 36,888 | 21,902 | 17,283 | 16,334 | 10,462 |
| Restructuring expenses | 0 | 8,713 | — | — | — | — | — | — |
| Total operating expenses | 113,833 | 216,525 | 230,348 | 168,901 | 88,938 | 72,323 | 76,249 | 57,162 |
| Other income (expense): | ||||||||
| Interest income | — | — | — | — | — | — | 1,398,000 | 910,000 |
| Interest income | 8,436 | 12,073 | 2,883 | 65 | 424 | 2,226 | — | — |
| Interest expense | — | (4,073) | (3,328) | (1,267) | (359) | (234) | — | — |
| Interest expense | (3,874) | — | — | — | — | — | — | — |
| Total other income (expense), net | 4,562 | 8,000 | (445) | (1,202) | 65 | 1,992 | 1,398 | 910 |
| Net loss | — | — | — | — | — | — | (64,257,000) | (38,707,000) |
| Loss before income taxes | (68,774) | — | — | — | — | — | — | — |
| Income tax expense | (418) | — | — | — | — | — | — | — |
| Net loss | (69,192) | (171,670) | (204,212) | (170,060) | (88,045) | (28,208) | — | — |
| Other comprehensive loss: | ||||||||
| Unrealized (loss) gain on marketable securities | (1) | 163 | (152) | 0 | (25) | 33 | 141 | (149) |
| Comprehensive loss | (69,193) | (171,507) | (204,364) | (170,060) | (88,070) | (28,175) | (64,116) | (38,856) |
| Net loss attributable to common stockholders - basic | (69,192) | (171,670) | (204,212) | (170,060) | (88,045) | (28,208) | (64,257) | (38,707) |
| Net loss attributable to common stockholders - diluted | (69,192) | (171,670) | (204,212) | (170,060) | (88,045) | (28,208) | — | (38,707) |
| Net loss per share attributable to common stockholders — basic and diluted (in dollars per share) | — | — | — | — | (1.43) | (0.65) | (2.79) | (3.22) |
| Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted (in shares) | — | — | — | — | 61,485,205 | 43,492,113 | 23,032,250 | 12,022,733 |
| Net loss per share attributable to common stockholders — basic (in dollars per share) | (0.56) | (1.48) | (2.18) | (2.41) | — | — | — | — |
| Net loss per share attributable to common stockholders — diluted (in dollars per share) | (0.56) | (1.48) | (2.18) | (2.41) | — | — | — | — |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic (in shares) | 122,539,598 | 116,112,891 | 93,654,243 | 70,580,949 | — | — | — | — |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — diluted (in shares) | 122,539,598 | 116,112,891 | 93,654,243 | 70,580,949 | — | — | — | — |
| Collaboration revenue | — | — | — | — | — | — | — | 17,545,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.